Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seer Inc Cl A (NQ: SEER )

2.500 +0.020 (+0.81%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Seer Inc Cl A

< Previous 1 2 Next >
Seer Ranked Number 57 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Attributes 2,440% revenue growth to increased adoption of its Proteograph™ Product Suite and exciting discoveries made by Seer customers across multiple areas of biology and disease 
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in Upcoming November Investor Conferences
From Seer, Inc.
Via GlobeNewswire
Seer Reports Third Quarter 2024 Financial Results
Growing enthusiasm for Proteograph Product Suite with multiple larger orders from government agencies and continued strong interest in STAC 
From Seer, Inc.
Via GlobeNewswire
Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
Collaboration enhances unprecedented access to deep, unbiased proteomics at scale, enabling deeper insights into human biology 
From Seer, Inc.
Via GlobeNewswire
Seer Highlights Capability of Deep Proteomics to Enhance Genomic Insights Into Alzheimer’s, Lung Cancer, and More at ASHG 2024
CoLab session with PrognomiQ and Salk Institute plus multiple presentations of new data offer firsthand look at multi-omic breakthroughs powered by Seer’s Proteograph™ Product Suite 
From Seer, Inc.
Via GlobeNewswire
Seer Showcases Scalable Proteomic Advancements Impacting Alzheimer’s, Population Health, and Xenotransplantation at HUPO 2024
Seer’s Proteograph™ Product Suite reveals new insights into Alzheimer’s pathways, drives population-scale plasma analysis, and captures immune dynamics in xenotransplantation—with additional... 
From Seer, Inc.
Via GlobeNewswire
Seer to Report Third Quarter 2024 Financial Results on November 6, 2024
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Seer, Inc.
Via GlobeNewswire
Seer Appoints Nicolas Roelofs to its Board of Directors
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Seer, Inc.
Via GlobeNewswire
Seer Reports Second Quarter 2024 Financial Results
Launched STAC in Europe and additional customer papers published in leading journals 
From Seer, Inc.
Via GlobeNewswire
Seer to Report Second Quarter 2024 Financial Results on August 8, 2024
From Seer, Inc.
Via GlobeNewswire
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
From Seer, Inc.
Via GlobeNewswire
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study
Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects 
From Seer, Inc.
Via GlobeNewswire
Seer Reports First Quarter 2024 Financial Results
Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications 
From Seer, Inc.
Via GlobeNewswire
Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
From Seer, Inc.
Via GlobeNewswire
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
From Seer, Inc.
Via GlobeNewswire
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data 
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in the TD Cowen 44th Annual Health Care Conference
From Seer, Inc.
Via GlobeNewswire
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
From Seer, Inc.
Via GlobeNewswire
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
From Seer, Inc.
Via GlobeNewswire
Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference
From Seer, Inc.
Via GlobeNewswire
Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
From Seer, Inc.
Via GlobeNewswire
Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500
Seer technology receives recognition for excellence in the field of proteomics 
From Seer, Inc.
Via GlobeNewswire
Seer Reports Third Quarter 2023 Financial Results
Expanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence 
From Seer, Inc.
Via GlobeNewswire
Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program
Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services 
From Seer, Inc.
Via GlobeNewswire
Seer to Report Third Quarter 2023 Financial Results on November 7, 2023
From Seer, Inc.
Via GlobeNewswire
Seer to Participate in Upcoming September Investor Conferences
From Seer, Inc.
Via GlobeNewswire
Seer Reports Second Quarter 2023 Financial Results
Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies 
From Seer, Inc.
Via GlobeNewswire
Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference
From Seer, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.